
	Age 0-14		Age 15-64		Age 65+		Total	
Year	Patients Count*	%†	Patients Count*	%†	Patients Count*	%†	Patients Count*	%
2016	6,000	2.2%	148,000	51.1%	135,000	46.8%	290,000	100%
2017	6,000	2.0%	153,000	50.2%	145,000	47.7%	304,000	100%
2018	6,000	1.9%	149,000	49.2%	148,000	48.9%	303,000	100%
2019	6,000	1.8%	150,000	48.0%	157,000	50.2%	313,000	100%
2020	4,000	1.4%	144,000	49.3%	144,000	49.3%	293,000	100%

### Number of patients with urine culture specimen collected, stratified by age group and surveillance year

### Number of patients with urine culture specimen collected, stratified by age group and surveillance year



<sup>\*</sup> Patient headcounts were rounded to the nearest thousand

<sup>†</sup> Percentages were rounded to one decimal place

<sup>§</sup> Patient headcount >0 and <500

## Number of patients with urine culture specimen collected, stratified by age group and surveillance year

	Prevalence of positive urine culture (%) (95%CI)							
Year	Age 0-14	Age 15-64	Age 65+	Total				
2016	400 / 6,300	14,100 / 147,900	28,600 / 135,500	43,100 / 289,600				
	(6.0%)	(9.5%)	(21.1%)	(14.9%)				
	(5.5%-6.6%)	(9.4%-9.7%)	(20.9%-21.3%)	(14.8%-15.0%)				
2017	400 / 6,200	14,200 / 152,700	30,300 / 145,300	44,900 / 304,200				
	(6.5%)	(9.3%)	(20.8%)	(14.8%)				
	(5.9%-7.1%)	(9.2%-9.5%)	(20.6%-21.0%)	(14.6%-14.9%)				
2018	400 / 5,800	14,300 / 149,300	31,300 / 148,300	46,000 / 303,400				
	(7.1%)	(9.6%)	(21.1%)	(15.2%)				
	(6.5%-7.8%)	(9.4%-9.7%)	(20.9%-21.3%)	(15.0%-15.3%)				
2019	400 / 5,600	14,700 / 150,300	33,200 / 157,100	48,200 / 313,000				
	(6.5%)	(9.7%)	(21.1%)	(15.4%)				
	(5.9%-7.2%)	(9.6%-9.9%)	(20.9%-21.3%)	(15.3%-15.5%)				
2020	300 / 4,200	13,500 / 144,200	29,200 / 144,400	43,000 / 292,800				
	(6.8%)	(9.3%)	(20.2%)	(14.7%)				
	(6.1%-7.6%)	(9.2%-9.5%)	(20.0%-20.5%)	(14.6%-14.8%)				

Patient head counts were rounded to the nearest hundred Percentages were rounded to one decimal place § Patient head count >0 and <50

# Number of patients with WHO GLASS priority organism isolated from positive culture specimen, stratified by location of onset

			Year	Year	Year	Year	Year
			2016	2017	2018	2019	2020
Community-onset	Escherichia coli	Number of patient with organism isolated*	23,900	24,700	25,000	26,100	23,300
		Percentage of patient with organism isolated <sup>+</sup>	65.23%	65.01%	64.52%	64.21%	64.12%
	Klebsiella	Number of patient with organism isolated*	2,500	2,600	2,700	3,200	3,100
	pneumoniae	Percentage of patient with organism isolated <sup>+</sup>	6.79%	6.81%	6.90%	7.82%	8.63%
	Other spp.	Number of patient with organism isolated*	13,300	13,900	14,300	14,900	12,900
		Percentage of patient with organism isolated <sup>+</sup>	36.39%	36.41%	36.89%	36.54%	35.44%
Hospital-onset	Other spp.	Number of patient with organism isolated*	4,800	5,200	5,500	5,700	5,100
		Percentage of patient with organism isolated <sup>+</sup>	56.67%	58.10%	58.76%	58.96%	59.41%
	Escherichia coli	Number of patient with organism isolated*	4,100	4,300	4,400	4,400	3,800
		Percentage of patient with organism isolated <sup>+</sup>	48.21%	48.14%	46.73%	45.48%	44.68%
	Klebsiella	Number of patient with organism isolated*	500	500	500	600	600
	pneumoniae	Percentage of patient with organism isolated <sup>+</sup>	5.55%	5.13%	5.59%	6.51%	7.42%
Undifferentiated	Klebsiella	Number of patient with organism isolated*	2,900	3,000	3,100	3,700	3,700
ocation of onset	pneumoniae	Percentage of patient with organism isolated <sup>+</sup>	6.72%	6.67%	6.77%	7.73%	8.56%
	Other spp.	Number of patient with organism isolated*	17,500	18,300	19,100	19,800	17,300
		Percentage of patient with organism isolated <sup>+</sup>	40.51%	40.82%	41.40%	41.16%	40.25%
	Escherichia coli	Number of patient with organism isolated*	27,000	28,100	28,400	29,600	26,300
		Percentage of patient with organism isolated <sup>+</sup>	62.66%	62.51%	61.80%	61.40%	61.19%

\* Patient headcounts were rounded to the nearest thousand

† Percentages were rounded to one decimal place

§ Patient headcount >0 and <500

# Distribution of WHO GLASS priority organism isolated from positive urine culture specimen, stratified by location of onset

		Pati	ent count and perce			
Location of onset	- origin	2016	2017	2018	2019	2020
Other spp.	Community	13300 (73.5%)	13900 (72.8%)	14300 (72.2%)	14900 (72.1%)	12900 (71.8%)
	Hospital	4800 (26.5%)	5200 (27.2%)	5500 (27.8%)	5700 (27.9%)	5100 (28.2%)
	Undifferentiated	17500 (100.0%)	18300 (100.0%)	19100 (100.0%)	19800 (100.0%)	17300 (100.0%)
Klebsiella pneumoniae	Community	2500 (84.1%)	2600 (85.0%)	2700 (83.6%)	3200 (83.4%)	3100 (83.2%)
	Hospital	500 (15.9%)	500 (15.0%)	500 (16.4%)	600 (16.6%)	600 (16.8%)
	Undifferentiated	2900 (100.0%)	3000 (100.0%)	3100 (100.0%)	3700 (100.0%)	3700 (100.0%)
Escherichia coli	Community	23900 (85.4%)	24700 (85.2%)	25000 (85.1%)	26100 (85.5%)	23300 (86.0%)
	Hospital	4100 (14.6%)	4300 (14.8%)	4400 (14.9%)	4400 (14.5%)	3800 (14.0%)
	Undifferentiated	27000 (100.0%)	28100 (100.0%)	28400 (100.0%)	29600 (100.0%)	26300 (100.0%)

[Report Footnote]:

\* Patient headcounts were rounded to the nearest hundred

<sup>†</sup> Percentages were rounded to one decimal place

§ Patient headcount >0 and <50

		Non-susceptibil	1ty % (95% CI) (Nu	imerator/Demonima	tor)		
		2016	2017	2018	2019	2020	
(Total headcount)	Location of Onset	(27000)	(28100)	(28400)	(29600)	(26300)	P-Value
amoxicillin and beta-lactamase inhibitor	Community	19.6% (19.1%-20.1%) (4700/23900)	19.7% (19.2%-20.2%) (4900/24700)	19.0% (18.5%-19.5%) (4800/25000)	20.7% (20.2%-21.1%) (5400/26100)	18.3% (17.8%-18.8%) (4300/23300)	↓ <0.05
Cefuroxime (IV)	Community	24.7% (24.1%-25.3%) (5200/20900)	24.5% (23.9%-25.0%) (5300/21600)	25.1% (24.5%-25.7%) (5500/21700)	25.2% (24.7%-25.8%) (5700/22500)	24.8% (24.2%-25.4%) (4900/19700)	-
Cefuroxime (oral)	Community	50.7% (50.0%-51.3%) (10300/20400)	49.0% (48.4%-49.7%) (10600/21600)	44.2% (43.5%-44.8%) (9600/21700)	41.6% (41.0%-42.3%) (9400/22500)	41.1% (40.4%-41.8%) (8100/19700)	↓ <0.01
levofloxacin	Community	34.8% (34.2%-35.5%) (6600/19100)	34.9% (34.3%-35.6%) (6900/19600)	35.0% (34.4%-35.7%) (6900/19800)	40.3% (39.6%-40.9%) (8600/21200)	44.4% (43.7%-45.1%) (8400/19000)	↑ <0.01
nitrofurantoin	Community	2.9% (2.7%-3.2%) (700/23900)	2.6% (2.4%-2.8%) (700/24700)	2.1% (1.9%-2.3%) (500/25000)	2.1% (2.0%-2.3%) (600/26100)	1.8% (1.6%-1.9%) (400/23300)	↓ <0.01
piperacillin and beta-lactamase inhibitor	Community	2.4% (2.2%-2.7%) (400/17900)	2.6% (2.4%-2.9%) (500/18700)	2.7% (2.4%-2.9%) (600/21000)	2.5% (2.3%-2.7%) (500/21800)	2.6% (2.4%-2.8%) (500/19000)	
sulfamethoxazole and trimethoprim	Community	39.2% (38.6%-39.9%) (8500/21800)	38.5% (37.9%-39.1%) (8700/22700)	37.7% (37.1%-38.3%) (8700/23000)	37.1% (36.5%-37.7%) (9000/24200)	34.8% (34.2%-35.5%) (7500/21500)	↓ <0.01

Non-susceptibility % (95% CI) (Numerator/Demonimator)

[Report Footnote]:

Patient headcounts were rounded to the nearest hundred

<sup>†</sup> Percentages were rounded to one decimal place

§ Patient headcount >0 and <50

<sup>+</sup><sup>+</sup><sup>+</sup> Since the susceptibility test was performed for less than 70% of isolates, readers should interpret the findings with caution \*\* P-value was calculated using Cochran-Armitage Test to examine whether a trend with statistical significance exists, only trends with statistical significance were reported.

Legend:  $\uparrow$  Increasing trend;  $\downarrow$  Decreasing trend

### Note:

Dataset was de-duplicated with consideration on location of onset

Total headcount refers to annual number of patients with particular bacteria isolated from blood/urine/stool

Proportion confidence intervals were calculated using the Wilson method

Non-susceptibility percentages calculated from less than 10 isolates (after de-duplication) were excluded from analysis

		Non-susceptibility % (95% CI) (Numerator/Demonimator)					
		2016	2017	2018	2019	2020	
(Total headcount)	Location of Onset	(27000)	(28100)	(28400)	(29600)	(26300)	P-Value
amoxicillin and beta-lactamase inhibitor	Hospital	27.5% (26.1%-28.8%) (1100/4100)	28.6% (27.2%-29.9%) (1200/4300)	26.9% (25.6%-28.2%) (1200/4400)	27.8% (26.5%-29.2%) (1200/4400)	27.8% (26.4%-29.3%) (1100/3800)	
Cefuroxime (IV)	Hospital	34.5% (33.1%-36.0%) (1400/4100)	33.7% (32.3%-35.2%) (1400/4300)	33.6% (32.2%-35.0%) (1500/4400)	34.5% (33.1%-35.9%) (1500/4400)	33.1% (31.7%-34.7%) (1300/3800)	
Cefuroxime (oral)	Hospital	61.0% (59.4%-62.5%) (2400/4000)	59.4% (57.9%-60.8%) (2600/4300)	54.6% (53.1%-56.0%) (2400/4400)	52.1% (50.6%-53.5%) (2300/4400)	50.9% (49.3%-52.5%) (1900/3800)	↓ <0.01
levofloxacin	Hospital	42.6% (40.8%-44.3%) (1300/3000)	41.7% (40.0%-43.4%) (1300/3100)	41.8% (40.1%-43.5%) (1300/3200)	44.2% (42.6%-45.9%) (1500/3300)	45.8% (44.0%-47.6%) (1300/2900)	↑ <0.01
nitrofurantoin	Hospital	4.3% (3.8%-5.0%) (200/4100)	3.7% (3.2%-4.3%) (200/4300)	2.4% (2.0%-3.0%) (100/4400)	2.2% (1.8%-2.7%) (100/4400)	1.7% (1.3%-2.2%) (100/3800)	↓ <0.01
piperacillin and beta-lactamase inhibitor	Hospital	5.0% (4.3%-5.7%) (200/3400)	5.4% (4.7%-6.2%) (200/3600)	5.1% (4.5%-5.8%) (200/4200)	4.2% (3.6%-4.8%) (200/4200)	5.1% (4.4%-5.9%) (200/3600)	-
sulfamethoxazole and trimethoprim	Hospital	45.4% (43.8%-47.0%) (1700/3700)	46.7% (45.2%-48.3%) (1900/4000)	45.6% (44.1%-47.1%) (1900/4100)	45.4% (43.9%-46.9%) (1900/4200)	43.9% (42.3%-45.6%) (1600/3500)	-

## Escherichia coli non susceptibility percentage of target organism for different antimicrobials

#### Escherichia coli non susceptibility percentage of target organism for different antimicrobials

[Report Footnote]:

Patient headcounts were rounded to the nearest hundred

<sup>+</sup> Percentages were rounded to one decimal place

§ Patient headcount >0 and <50

<sup>++</sup> Since the susceptibility test was performed for less than 70% of isolates, readers should interpret the findings with caution

\*\* P-value was calculated using Cochran-Armitage Test to examine whether a trend with statistical significance exists, only trends with statistical significance were reported.

Legend: ↑ Increasing trend; ↓ Decreasing trend

### Note:

Dataset was de-duplicated with consideration on location of onset

Total headcount refers to annual number of patients with particular bacteria isolated from blood/urine/stool

Proportion confidence intervals were calculated using the Wilson method

Non-susceptibility percentages calculated from less than 10 isolates (after de-duplication) were excluded from analysis